[Protective effect of ketamine against septic shock in rats].
OBJECTIVE
To investigate the effects and the mechanism of ketamine on hemodynamics and pro-inflammatory cytokine levels of plasma in septic shock rats.


METHODS
Cecal ligation and puncture (CLP) was used to reproduce septic shock model. Twenty healthy and male Sprague-Dawlay (SD) rats weighing (225+/-25) g were randomly divided into four equal groups: Sham CLP group, CLP group, ketamine I (KT I) and ketamine II (KT II) group. Thirty minutes before CLP, normal saline (0.9 %) was infused continuously at a rate of 5 ml.kg(-1).h(-1) through the left femoral vein cannula in sham CLP and CLP group, and ketamine (5 mg.kg(-1).h(-1) and 10 mg.kg(-1).h(-1), respectively) was infused continuously in KT I or KT II group. The right femoral artery was cannulated to monitor mean arterial pressure. The plasma levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) were measured using enzyme-linked immunosorbent assays (ELISA).


RESULTS
CLP produced progressive hypotension, and a large increase in the plasma TNF-alpha and IL-6 concentrations. The hemodynamic responses were reversed and the cytokine responses were suppressed in ketamine treated animals.


CONCLUSIONS
Ketamine administration has protective effect against septic shock in CLP rats.
Song
Xue-Min
XM
Department of Anesthesiology, Zhongnan Hospital, Wuhan University, Wuhan 430071, Hubei, China. sxmcl1018@163.com
Li
Jian-Guo
JG
Wang
Yan-Lin
YL
Zhou
Qing
Q
Du
Zhao-Hui
ZH
Jia
Bao-Hui
BH
Hu
Zheng-Fang
ZF
Li
Pei
P
D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D004195:Disease Models, Animal; D006439:Hemodynamics / Q000187:drug effects; D015850:Interleukin-6 / Q000097:blood; D007649:Ketamine / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012772:Shock, Septic / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000700:Analgesics; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D007649:Ketamine